Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | PDE4A | P27815 | 8/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021010 | 1.00 | KMT2A (0.51) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL4768114 | 1.00 | KMT2A (0.51) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL6021708 | 0.99 | KMT2A (0.52) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL6020854 | 0.96 | KMT2A (0.49) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL6021117 | 0.93 | KMT2A (0.44) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL4764586 | 0.91 | KMT2A (0.48) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL4766399 | 0.91 | KMT2A (0.48) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL4762952 | 0.91 | KMT2A (0.48) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL6026200 | 0.90 | KMT2A (0.47) | KMT2ASTING1PDE4BPDE4DPDE4A | |
| SCHEMBL6025152 | 0.90 | KMT2A (0.47) | KMT2ASTING1PDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | MALT1, CYP1B1, WEE2 | KMT2A 3218/4885STING1 2586/4885PDE4B 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.